Clinical Trial Update: CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A multi-phase early-stage clinical trial evaluating CAR-T cell therapy for relapsed or refractory hematologic malignancies including leukemia and lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma of Bone

Drugs mentioned

• CAR-T cell therapy

Snippet

Sponsor: Hebei Senlang Biotechnology Inc., Ltd. | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN